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Multiple myeloma (MM) accounts for 1% of all malignancies, 10% 
of all haematological malignancies in whites and 20% in African 
Americans.[1] Two meta-analyses covering the USA, Australia, Italy, 
Switzerland and the UK showed an increased incidence of MM in 
HIV-positive patients, with a standardised incidence rate of 2.71 
(95% confidence interval (CI) 2.13 - 3.44) and a relative risk (RR) of 
1.9 - 6.5.[2,3] This differs from the relative risk in South African (SA) 
studies, in which an RR of 0.7 - 0.9 was described,[4,5] which could 
be attributed to under-reporting and earlier death from other AIDS-
related illnesses.
The pathogenic mechanisms associated with the proposed 
increased frequency of MM in HIV patients compared with the 
general population are not well understood, and several possibilities 
have been reviewed.[6] Although HIV probably does not play a 
direct role in the pathogenesis of MM, as it can neither infect B-cells 
or plasma cells nor drive their malignant transformation, several 
indirect mechanisms may be involved in the pathogenesis of plasma-
cell neoplasias in HIV-associated cases.[7]
Polyclonal hypergammaglobulinaemia resulting from chronic 
B-cell stimulation and loss of normal T-cell function, as seen in the 
setting of HIV infection, could result in an inclination towards the 
development of MM in genetically predisposed individuals. Also, 
several case reports have been presented in which the monoclonal 
antibody was shown to react with HIV-specific antigens, suggesting 
that HIV antigens may act as super-antigens and directly stimulate 
the proliferation of malignant plasma cells.[8-11] Furthermore, 
immunodeficiency caused by HIV-induced T-cell depletion was 
found to increase the risk of developing several types of cancer, 
including MM.[3]
Over the past three decades, much has changed in the treatment 
and outcomes of patients suffering from both MM and HIV. 
Until recently, only case reports had been published, mostly on 
HIV-positive MM patients with unusual clinical presentations and 
aggressive clinical courses.[12-15] Many of these studies highlight the 
difficulties in diagnosis of MM in HIV-positive patients, as the two 
diseases share some common clinical features, especially anaemia, 
fatigue, weight loss, bone marrow plasmacytosis, renal insufficiency 
and recurrent bacterial infections. In 2014, Li et al.[16] published a 
retrospective analysis of 10 symptomatic HIV-positive MM patients 
treated for both conditions. They found that HIV-positive patients on 
highly active antiretroviral therapy had significantly superior overall 
survival and progression-free survival compared with their HIV-
negative counterparts, making early recognition of patients suffering 
from both diseases even more necessary. In contrast to what might be 
suspected from cases described previously, no significant differences 
were found in the characteristics of the HIV-positive patients 
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compared with their HIV-negative counterparts, with age, gender, 
renal function, bone lesions and stage of disease all being similar.[16]
Other recently published case reports and single-centre experiences 
have shown similar favourable responses and increased survival in 
HIV-positive MM patients treated with either thalidomide-based 
chemotherapy or myeloablative chemotherapy and autologous stem-
cell transplantation.[16-20] In a phase I study, the HIV protease inhibitor 
nelfinavir was considered safe and showed promising activity in 
patients with advanced bortezomib-refractory MM by triggering the 
unfolded protein response and thereby overcoming the biological 
features of proteasome inhibitor resistance in these patients.[21]
Objective
To investigate the presenting features of HIV-positive patients newly 
diagnosed with MM. These patients were compared with HIV-
negative MM patients from the same population to identify specific 
features that might be useful in the early recognition of HIV infection 
in MM patients.
Methods
A retrospective descriptive study was performed to investigate the 
demographic and clinical profile of HIV-positive MM patients at 
first presentation at Universitas Academic Hospital Complex in 
Bloemfontein, SA, a tertiary referral centre. This retrospective cohort 
study compared HIV-positive patients diagnosed with MM with 
HIV-negative MM patients. All patients diagnosed with MM during 
the period 1 January 2004 - 31 December 2011 with an HIV test result 
available were included in this study. Diagnosis was based on the then 
current diagnostic criteria of the International Myeloma Working 
Group of 2003 and clinical opinion of the haemato-oncologist, 
and may not meet the diagnostic criteria currently used.[22] All 
plasmacytomas were histologically confirmed. The stage of disease 
was based on the International Staging System (ISS), which relies on 
serum albumin and β2-microglobulin (B2M) levels.[23]
Statistical analysis
Data were analysed by the Department of Biostatistics at the 
University of the Free State, Bloemfontein, using the SAS 9.3 
programme (SAS Institute, USA) for the frequency procedure, 
and Student’s t-test and the χ2 test (with Fisher’s exact test) where 
applicable. For non-parametric data, differences were tested by 
computing the median difference scores as proposed by Campbell 
and Gardner.[24]
Ethical approval
Ethical approval to conduct the study was obtained from the Ethics 
Committee of the Faculty of Health Sciences, University of the Free 
State (ref. no. ETOVS 187/2010).
Results
Of 146 patients diagnosed with MM during the study period, 89 
(61.0%) had an HIV test result available and were included in 
the study. Of these 89 patients, 16 (18.0%) were HIV-positive. 
Characteristics of the HIV-positive cases are summarised in Table 1. 
The results of the comparison of HIV-positive and HIV-negative 
patients are summarised in Tables 2 and 3.
Demographics
The median age of the HIV-positive patients was 51 years (range 
36 - 68), which was significantly lower than that of the HIV-negative 
patients, with a median difference of 7 years (95% CI 2 - 13). The 
male/female ratio in the HIV-negative patients was 1:1, compared 
with 3:1 in the HIV-positive group. In the HIV-negative group, 
55  patients (75.3%) were black, 10 (13.7%) white and 7 (9.6%) of 
mixed ethnicity, while 15 patients (93.8%) in the HIV-positive group 
were black and 1 (6.3%) was of mixed ethnicity.
HIV status
HIV was newly diagnosed during the work-up of MM in eight cases 
(50.0%). In case 2, the diagnosis of HIV was made 5 months after the 
initial presentation of MM. This patient was included on the basis 
of his low CD4 count and the high probability of his already having 
HIV at the time of being diagnosed with MM. For the other cases, the 
median time between the diagnosis of HIV and the presentation of 
MM was 6 months (mean 23, range 2 - 69). Only two patients (12.5%) 
were on combined antiretroviral treatment (cART) at presentation 
with MM. The CD4 count was known for all the HIV-positive 
patients (median 212 cells/µL, range 65 - 625).
MM staging
Neither the median serum albumin levels nor B2M levels were 
significantly different between the two groups. The stage distribution 
based on the ISS was also similar (Table 4). In the HIV-negative 
group, immunoglobulin G (IgG) and IgA paraproteins and myeloma 
light-chain disease were mainly seen, while in the HIV-positive 
group only IgG paraproteins were found (Table 5). The percentage 
of patients with a newly diagnosed plasmacytoma at the time of 
presentation was not significantly different between the HIV-positive 
and HIV-negative groups.
Bone marrow and radiographic findings
No significant difference between the two groups was found for the 
median percentages of bone marrow plasma cells. Of the radiographic 
variables, the only difference was a significantly lower prevalence of 
osteolytic lesions in the HIV-positive group (73% v. 93%; p=0.03), 
but no significant differences were seen for pathological fractures and 
vertebral collapse.
Laboratory findings
The median serum creatinine level was significantly lower in the 
HIV-positive patients than in those who were HIV-negative, with 
a median difference of 20 µmol/L (95% CI 2 - 45). No significant 
difference was found for the percentages of patients presenting 
with Bence-Jones proteinuria. The median 24-hour measurement 
of protein in the urine was not significantly lower in HIV-positive 
patients, with a median difference of 0.43 g/24 h (95% CI –0.027 - 
0.95). The serum Freelite kappa/lambda ratio was abnormal in 91% of 
HIV-negative and 69% of HIV-positive patients (p=0.08).
The median platelet count was not significantly lower in the 
HIV-positive patients, with a median difference of 54 × 109/L (95% 
CI  –2 - 117). In the HIV-negative group, 1% of the patients were 
severely thrombocytopenic (<50 × 109/L), compared with 13% in the 
HIV-positive group. The lymphocyte count was only slightly lower in 
the HIV-positive patients, with a median difference of 0.21 × 109/L 
(95% CI –0.13 - 0.62). The neutrophil count was significantly lower 
in the HIV-positive patients, with a median difference of 1.13 × 109/L 
(95% CI 0.16 - 2.4). There was a higher proportion of patients with 
a low neutrophil count (<2 × 109/L) in the HIV-positive group than 
among those who were HIV-negative (31% v. 11%).
Discussion
Although only two of the HIV-positive patients were on cART 
therapy at the time of diagnosis of MM, this group presented with 
comparable ISS stage of disease, pathological fractures, bone marrow 
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plasmacytosis, plasmacytomas, haemoglobin concentrations and 
platelet and lymphocyte counts to their HIV-negative counterparts. 
The gender distribution in the two groups was also similar. In contrast, 
the HIV-positive patients differed significantly from those who were 
HIV-negative in presenting at a younger age and having fewer 
osteolytic lesions, lower neutrophil counts and lower serum creatinine 
levels. Other notable findings were the high rate of newly diagnosed 
HIV patients, and the relatively high CD4 counts, the lower prevalence 
of abnormal serum Freelite kappa/lambda ratios and the exclusive-
ness of the IgG paraproteins in the HIV-positive group.
A possible limitation in the method used for this study that 
should be taken into account when interpreting further results, is 
the inclusion of all patients diagnosed with MM based on the then 
current diagnostic criteria of the International Myeloma Working 
Group of 2003 and clinical opinion of the haemato-oncologist.[22] 
During the time period of the study, diagnostic criteria for MM 
have changed multiple times, and according to the leading criteria 
stated by the International Myeloma Working Group, patients 11, 14 
and 15 may not have suffered from MM at that particular time.[25] 
A solitary plasmacytoma with minimal bone marrow involvement 
and asymptomatic MM cannot be ruled out in these patients. 
Because the same changes in diagnostic criteria have occurred in 
the HIV-negative group, trends in differences between both groups 
will remain valuable, and the researchers have decided to keep these 
patients included in the analysis.
Demographics
Although age was significantly lower in the HIV-positive group than 
in the HIV-negative group, it is not comparable to the median age 
of 37 years described in the largest review of case reports of plasma 
cell tumours in HIV-positive patients.[26] Li et al.[16] found ages and 
age differences that are comparable to our study. In contrast, the age 
difference was not significant in this study, possibly owing to their 
small population size.[16] Many cancers are diagnosed at a younger 
age in HIV-positive patients than among uninfected individuals.[27] 
One explanation for the lower age in the HIV-positive group may 
be that HIV infection is more prevalent among younger adults than 
elderly patients.
The ethnic distribution in the HIV-negative group reflects the 
population of the region in which the study was performed, where 
Table 4. Comparison of ISS staging of HIV-positive and 
HIV-negative MM patients
MM stage
HIV-negative 
(N=73), n (%)
HIV-positive 
(N=16), n (%)
ISS stage I 4 (5.5) 1 (6.3)
ISS stage II 28 (38.4) 6 (37.5)
ISS stage III 42 (57.5) 9 (56.3)
ISS = International Staging System; MM = multiple myeloma.
Table 5. Immunoglobulin paraproteins found in HIV-
positive and HIV-negative MM patients
Immunoglobulin 
paraprotein
HIV-negative 
(N=73),
n (%)
HIV-positive 
(N=16),
n (%)
IgGκ 36 (49.3) 10 (62.5)
IgGλ 16 (21.9) 6 (37.5)
IgAκ 4 (5.5) -
IgAλ 8 (11.0) -
κ light chain 7 (9.0) -
λ light chain 2 (2.7) -
MM = multiple myeloma.
Table 2. Comparison of age and laboratory values in HIV-positive and HIV-negative MM patients
Variable
HIV-negative (N=73) HIV-positive (N=16) Results
Patients 
with 
data, n Median Range
Patients 
with 
data, n Median Range
Median 
difference
Lower 
CI
Upper 
CI Significant
Age (yr) 73 59 38 - 79 16 50.5 36 - 68 7 2 13 Yes
Serum creatinine (µmol/L) 73 91 40 - 1 666 16 76.5 45 - 225 20 2 45 Yes
Proteinuria (g/24 h) 47 1.08 0.04 - 11.2 13 0.59 1.10 - 2.21 0.43 –0.03 0.95 No
Haemoglobin (g/dL) 73 9.7 3.2 - 15.8 16 9 4.3 - 13.9 0.3 –1.3 1.9 No
Platelet count (× 109/L) 73 247 49 - 741 16 187 15 - 436 54 –2 117 No
Lymphocyte count (× 109/L) 69 2 0.5 - 4.4 16 1.7 0.9 - 2.2 0.21 –0.13 0.62 No
Neutrophil count (× 109/L) 70 4.2 1.1 - 12.2 16 3 1.2 - 7.4 1.13 0.16 2.4 Yes
MM = multiple myeloma.
Table 3. Comparison of plasmacytoma prevalence and bone involvement in HIV-positive and HIV-negative MM patients
Variable
HIV-negative
(N=73)
HIV-positive
(N=16) Results
Patients with 
data, n Yes, n (%)
Patients with 
data, n Yes, n (%) Difference, % p-value
Plasmacytoma at presentation 66 17 (25.8) 12 6 (50.0) –24.2 0.16
History of bone pain 70 63 (90.0) 11 11 (100) –10.0 0.59
Osteolytic lesions 70 65 (92.9) 15 11 (73.3) 19.6 0.03
Pathological fracture 66 18 (27.3) 13 4 (30.8) –3.5 0.75
Vertebral collapse 64 28 (43.8) 13 6 (46.2) –2.4 1.00
MM = multiple myeloma.
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79.5% were black, 9% white and 9% of mixed ethnic origin.[28] The 
high percentage of blacks and the absence of whites in the HIV-
positive group reflects the distribution pattern of HIV in the region.
HIV status
Fifty percent of the HIV-positive patients in this study were newly 
diagnosed with HIV during their work-up for MM. This finding is 
consistent with other case reports and reviews, where HIV infection 
was newly discovered during the evaluation for MM, and where it 
was previously stated that MM should be considered as a presenting 
symptom of HIV infection.[12,13,29] Only two patients in our study were 
on cART at presentation with MM, and six patients were known to be 
HIV-positive but were not on therapy. Five of these six patients had 
a CD4 count of <350 cells/µL, the current level for initiation of cART 
in SA.[30] During the period of this study, however, the cut-off for the 
initiation of ART changed from <200 cells/µL to the new count of 
350 cells/µL, which may explain why so many of our HIV-positive 
patients were not on therapy at the time of diagnosis of MM.[30]
The HIV-positive patients in this study presented with relatively 
high CD4 counts, in contrast to patients with HIV-related non-
Hodgkin lymphomas, most of whom have more advanced HIV 
infection and a CD4 count <100 cells/µL.[31,32] Our findings are in line 
with the even higher CD4 counts in the HIV-positive MM patients 
studied by Li et al.[16] Konstantinopoulos et al.[33] performed protein 
electrophoreses and measured quantitative immunoglobulin levels 
in samples from 320 consecutive HIV-positive patients. Younger 
age and higher CD4 cell counts were significantly associated with 
monoclonal or oligoclonal banding, suggesting that younger HIV-
positive patients with a more robust immune system (reflected by a 
higher CD4 count), which in this case is stimulated by uncontrolled 
viraemia, are most likely to have an augmented B-cell response 
to HIV infection. One manifestation of this B-cell response is 
low-concentration monoclonal banding in 4.4% of the patients 
studied.[33] Whether this low-concentration monoclonal banding is 
premalignant and will progress to a malignant plasma cell neoplasm, 
such as monoclonal gammopathy of undetermined significance in a 
normal population, is unclear.
Multiple myeloma staging
All the HIV-positive patients in this study presented with IgGκ or 
IgGλ paraproteins, with a predominance of light chains of the κ type 
(κ:λ ratio 1.8). Two patients (12.5%) presented with three monoclonal 
protein peaks. No patient had MM with another immunoglobulin 
subtype, light-chain disease or non-secretory myeloma, which were 
also reported previously to be rare. In a study of 1 027 almost 
exclusively white MM patients, only 52% of the serum monoclonal 
proteins were of the IgG type.[34] Briault et al.[35] investigated the 
classes, subclasses and light-chain types of 78 serum monoclonal 
immunoglobulins from adult patients affected with various forms 
of HIV infection, and found that 91% were of the IgG class and 9% 
IgM, with a predominance of light chains of the λ  type (κ:λ ratio 
0.6). The subclass distribution of IgG was strikingly different from 
that observed in MM, with much less IgG1 and much more IgG3 
and IgG4.[35] Ng et al.[8] presented seven cases of HIV-associated 
paraproteinaemia, of which five were with IgG1κ, one with IgG3λ 
and one with IgAλ. All IgG1κ paraproteins were reactive against HIV 
gag and pol antigens, while the other two types of paraproteins were 
not reactive to specific HIV antigens.[8] Three other studies reported 
paraproteins that were specific for the HIV p24 and p31 antigens, and 
all paraproteins were of the IgGκ type.[9-11]
Lefrère et al.[36] screened 341 asymptomatic HIV patients for over 
6  years and found 11 cases of monoclonal gammopathy; again all 
para proteins were of the IgGκ and IgGλ type. These data may suggest 
a possible role for antigenic stimulation directly by the HIV virion or 
other antigens in the pathogenesis of plasma-cell neoplasms in HIV-
associated cases, and may indicate a causative role for HIV or an HIV-
associated infection in MM. In contrast, in the study of Li et al.[16] only 
seven out of 10 HIV-positive MM patients showed paraproteins of the 
IgG type and three patients were found to have an IgA paraprotein, 
κ-light chain disease or non-secretory myeloma. [16] Previous studies 
have shown that patients with IgG-type MM have a better prognosis 
than those with IgA MM. Whether this is true in patients with HIV-
associated MM will require evaluation in future research.
The HIV-negative group had a higher percentage of patients 
with an abnormal serum Freelite kappa/lambda ratio than the HIV-
positive group. No studies could be found on this phenomenon in 
the HIV context, but it may be due to the effects of HIV infection 
on immunoglobulin levels. Hypergammaglobulinaemia is a feature 
of many chronic infections and is well recognised in HIV-positive 
individuals, in whom it often occurs in combination with a defective 
humoral immunity.[37,38] Immunoglobulin levels become elevated 
from early stages of HIV-1 infection as a result of both specific and 
polyclonal activation of hyper-reactive naive B-cells.[39] As polyclonal 
kappa and lambda light-chain production is not usually equal, an 
elevation in immunoglobulins may counterbalance the serum Freelite 
kappa/lambda ratio and lead to a false-normal value.
Bone marrow and radiographic findings
The significantly lower percentage of osteolytic lesions in the HIV-
positive patients may have been due to their lower percentage of bone 
marrow plasma cells, as MM cells activate osteoclasts and influence 
the bone marrow environment, thereby promoting lytic bone 
lesions. [40] In contrast, no differences were found in the prevalences 
of pathological fractures and vertebral collapses, which represent a 
huge cause of morbidity in MM patients. Whether the younger age in 
the HIV-positive group could possibly have been protective against 
the development of osteolytic lesions requires further investigation.
Laboratory findings
Although the glomerular filtration rate was not measured, the 
significantly lower serum creatinine levels and lower levels of 
proteinuria suggest relatively good renal function in the HIV-positive 
patients. This presumably lower prevalence of renal involvement 
in HIV-positive MM patients has not been reported previously. A 
reason for this phenomenon may be the younger age of the HIV-
positive patients, and the fact that renal function declines with age and 
polypharmacy is usually more frequent among elderly patients.
The median numbers of platelets, lymphocytes and neutrophils 
were all lower in the HIV-positive patients than in those who were 
HIV-negative, but only the neutrophils were significantly lower. 
Neutropenia was found three times more frequently in the HIV-
positive group. The incidence of neutropenia usually correlates 
directly with the degree of immunosuppression in HIV and varies 
from 5 - 10% in the early asymptomatic stages of infection to as 
high as 50 - 70% among patients with advanced disease.[41] The 
cause of neutropenia is often multifactorial in HIV-positive patients, 
representing the combined effects of systemic infection, medications 
and HIV itself.
Conclusion
Even though studies have indicated an increased prevalence of MM 
in the HIV-positive population, very little was known about the 
demographic and clinical presentation of patients simultaneously 
suffering from both MM and HIV. This study represents the largest 
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series of patients from a single centre and shows how similar the 
initial presentation of MM is in HIV-positive and HIV-negative 
patients. HIV-positive MM patients do present at a significantly 
lower age and with fewer osteolytic lesions, lower neutrophil counts, 
less renal impairment and fewer cases with abnormal Freelite kappa/
lambda ratios, and all M-proteins were of the IgG subtype. Except 
for the lower age, none of these findings are really specific enough to 
enable early recognition of these patients. Half of our patients were 
diagnosed with HIV during the work-up of MM, showing that MM 
could be seen as a presenting symptom of HIV, and as only 61% of 
the patients diagnosed with MM in our period of study had an HIV 
test result available, it is not unlikely that some HIV infections were 
missed. Especially since recent publications are showing trends of 
better overall and progression-free survival of HIV-positive MM 
patients compared with their HIV-negative counterparts, delayed 
or overlooked diagnosis of HIV would be a missed opportunity 
for early initiation of both antiretroviral therapy and treatment of 
the myeloma. We suggest that HIV infection should be tested for 
routinely in younger MM patients, especially in areas with a high 
prevalence of HIV. Because of the high prevalence of HIV infection 
in SA, and its possible implications with regard to treatment, it could 
be suggested that HIV should be tested for routinely in all patients 
newly diagnosed with a malignancy. Prospective studies are required 
to evaluate and compare different treatment strategies and outcomes 
of HIV-positive individuals with myeloma compared with their HIV-
negative counterparts. In addition, larger prospective multicentre 
studies are needed to confirm some of the trends that did not reach 
statistical significance in this study, and leading diagnostic criteria for 
the diagnosis of MM should be used.
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